Comparing the efficacy of Mirabegron in reducing urinary symptoms associated with cerebrovascular accidents
Phase 4
- Conditions
- Health Condition 1: I69- Sequelae of cerebrovascular disease
- Registration Number
- CTRI/2023/03/050511
- Lead Sponsor
- DEPARTMENT OF UROLOGY KASTURBA MEDICAL COLLEGE MANIPA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients with Cerebrovascular accident having moderate/bothersome LUTS as per IPSS questionnaire
Exclusion Criteria
Patients with:
1. Montreal Cognitive Assessment score <24,
2. Poorly controlled diabetes or poorly controlled hypertension,
3. Indwelling catheter,
4. Renal dialysis
5. Cardiac failure requiring diuretics
6. Urinary tract infection at presentation
7. Prostate or bladder cancer
8. Uncontrolled bladder outlet obstruction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome measures: Change in the objectively measurable parameters namely: <br/ ><br>1. Change in day time urinary frequency 2. Change in number of nocturia episodes 3. Change in functional bladder capacity 4. Change in QmaxTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method Change in the <br/ ><br>1. IPSS score <br/ ><br>2. OABSS (Over Active Bladder Symptom Score) <br/ ><br>3. OAB-q SF Score <br/ ><br>4. Patient Perception of Bladder Condition (PPBC) <br/ ><br>5. OAB family impact measure (OAB-FIM) score <br/ ><br>Timepoint: 4 WEEKS, 8 WEEKS AND 12 WEEKS